Forward PE Ratio: 13.33
The forward PE ratio is 13.33 as of Thursday, July 9, 2026.
Forward PE Ratio (13.33) = Close Price ($44.99) / Consensus Forward EPS ($3.36)
BSX Forward PE Ratio Metrics
FORWARD PE RATIO
13.33
BSX Competitors' Forward PE Ratio
Boston Scientific Corporation
Market Cap
$66.87B
Forward PE Ratio
13.33
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Boston Scientific Corporation (BSX) | $66.87B | 13.33 |
| Regeneron Pharmaceuticals, Inc. (REGN)vs › | $68.81B | 14.31 |
| Cencora, Inc. (COR)vs › | $58.85B | 17.41 |
| Cigna Corporation (CI)vs › | $77.19B | 9.51 |
| Cardinal Health, Inc. (CAH)vs › | $54.75B | 22.02 |
| Becton, Dickinson and Company (BDX)vs › | $54.65B | 11.96 |
| Edwards Lifesciences Corporation (EW)vs › | $52.59B | 31.10 |
| Humana Inc. (HUM)vs › | $47.76B | 44.80 |
| IDEXX Laboratories, Inc. (IDXX)vs › | $44.06B | 37.91 |
| HCA Healthcare, Inc. (HCA)vs › | $90.73B | 13.58 |
Trailing vs Forward
Trailing P/E
18.8
reported TTM EPS
Forward P/E
13.3
consensus next-FY EPS
The gap between the two multiples is the consensus growth expectation: analysts' forward EPS of $3.36 implies +41.2% EPS growth vs the reported trailing $2.38.
Forward P/E by Fiscal Year
View All Analyst EstimatesAt today's $44.99 close, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $3.36 | $3.32 – $3.39 | 16 | 13.4x |
| 2027-12-31 | $3.71 | $3.61 – $3.81 | 17 | 12.1x |
| 2028-12-31 | $4.13 | $3.70 – $4.63 | 8 | 10.9x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
Forward PE Ratio Formula & Definition
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Forward PE Ratio FAQ
- What is the forward PE ratio for Boston Scientific Corporation (BSX)?
- The forward PE ratio for BSX stock is 13.33.
Related Metrics
About Boston Scientific Corporation
Boston Scientific Corporation (BSX) operates as a global leader in medical technology, specializing in the design, manufacturing, and commercialization of innovative medical devices tailored for a diverse array of interventional medical specialties across the globe. Its business is strategically organized into three principal segments: MedSurg, Rhythm and Neuro, and Cardiovascular. Within these divisions, the company provides a comprehensive portfolio of solutions addressing various gastrointestinal and pulmonary ailments, as well as urological and pelvic health concerns. This extends to advanced implantable devices for managing cardiac rhythm disorders, such as cardioverter-defibrillators, cardiac resynchronization therapy devices, and pacemakers, complemented by remote patient management systems. Furthermore, Boston Scientific offers sophisticated technologies for diagnosing and treating complex heart rate and rhythm irregularities. These encompass 3-D cardiac mapping and navigation tools, along with a suite of specialized catheters (including ablation, diagnostic, mapping, and intracardiac ultrasound types), delivery sheaths, and related accessories. Its offerings also extend to neurological conditions, providing spinal cord stimulator systems for chronic pain management, indirect decompression systems, and deep brain stimulation systems. In the realm of interventional cardiology, the company's innovations include drug-eluting coronary stent systems designed for treating coronary artery disease, products for percutaneous coronary interventions to combat atherosclerosis, and intravascular imaging catheters (such as ultrasound and fractional flow reserve devices) for assessing coronary arteries, heart chambers, and peripheral vessels. It also develops structural heart therapies. Beyond this, Boston Scientific supplies an array of stents, balloon catheters, wires, and atherectomy systems for the treatment of arterial diseases. For venous conditions, it provides thrombectomy and acoustic pulse thrombolysis systems, alongside wires and stents. Critically, the company also contributes to cancer treatment through peripheral embolization devices, radioactive microspheres, various ablation systems (including cryotherapy), and micro and drainage catheters. The organization was established in 1979 and maintains its corporate headquarters in Marlborough, Massachusetts.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Michael F. Mahoney